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A total of 22 Cryptosporidium isolates from human immunodeﬁciency virus-infected patients from Kenya,
Switzerland, and the United States were examined at three genetic loci: the 18S ribosomal DNA, HSP-70, and
acetyl coenzyme A synthetase genes. Four distinct Cryptosporidium genotypes were identiﬁed: (i) the Crypto-
sporidium parvum “human” genotype, (ii) the C. parvum “cattle” genotype, (iii) Cryptosporidium felis, and (iv)
Cryptosporidium meleagridis. This is the ﬁrst report of C. meleagridis in a human host. These results and those
of others indicate that immunocompromised individuals are susceptible to a wide range of Cryptosporidium
species and genotypes. Future studies are required to understand the full public health signiﬁcance of Crypto-
sporidium genotypes and species in immunocompromised hosts.
Cryptosporidium is an important enteric pathogen that
causes diarrheal illness in humans and animals (4). In immu-
nocompetent individuals, infection is usually self-limiting, but
in immunocompromised individuals receiving immunosup-
pressive drugs and human immunodeﬁciency virus (HIV)-in-
fected individuals, persistent infections which can be life
threatening may develop (3). Cryptosporidium may account for
10 to 20% of the cases of diarrhea in HIV-infected patients
living in developed countries and as much as 50% in under-
privileged countries (12, 16). Among HIV-infected individuals
who contracted cryptosporidiosis as a result of the infamous
outbreak in Milwaukee, Wis., in 1993, the outcome of disease
was severe, with greater than 50% mortality within 6 months to
a year after the outbreak (I. Gilson, B. P. Buggy, C. F. Brun-
nitt, M. Busalacchi, and K. Ivantic, Int. Conf. AIDS, 1994).
The genus Cryptosporidium is a member of the phylum Api-
complexa along with the related genera Toxoplasma, Eimeria,
and Plasmodium. To date, eight named species of Cryptospo-
ridium have been proposed as valid. These include C. parvum
from many mammals, C. muris from rodents and ruminants,
C. felis from cats, C. wrairi from guinea pigs, C. meleagridis and
C. baileyi from birds, C. serpentis from reptiles, and C. nasorum
from ﬁsh (4, 9).
The causative agent of cryptosporidiosis in humans and a
range of mammalian species is the species C. parvum. Recent-
ly, it has become increasingly clear, however, that C. parvum is
not a single species but is composed of a number of distinct
genotypes: a “human” genotype which has so far been found
only in humans; a “cattle” genotype which is found in domestic
livestock such as cattle, sheep, and goats and which can also
infect humans; a “mouse” genotype which has been found in
mice from around the world and more recently in bats; a “pig”
genotype which is found in pigs; a “marsupial” genotype that
has been found in koalas and kangaroos; and “dog” and “fer-
ret” genotypes which have to date been found only in the re-
spective hosts (7, 9, 18). Only the human and cattle genotypes
have so far been identiﬁed in immunocompetent humans, and
the public health signiﬁcance of the remaining genotypes is
unknown.
The susceptibilities of immunocompromised individuals to
genotypes of C. parvum and to other species of Cryptospori-
dium have not been extensively studied. The aim of the project
described here was to genetically characterize isolates of Cryp-
tosporidium from HIV-infected individuals in order to deter-
mine the public health signiﬁcance of genotypes of C. parvum
and other species of Cryptosporidium.
MATERIALS AND METHODS
Sources of parasite isolates, diagnosis, and clinical information. The sources
of the parasite isolates are listed in Table 1 (see the Results section). Swiss
isolates were collected between February 1992 and July 1995; Kenyan isolates
were collected between January 1998 and January 1999. Isolates of Cryptospo-
ridium from the United States were collected from 1997 to 1998. Stool specimens
were examined by Kinyoun carbol-fuchsin modiﬁed acid-fast staining, and an
aliquot of each positive stool was stored either in 2.5% dichromate at 4°C or
without preservatives at 280°C until molecular analysis. In Switzerland, socio-
demographic, clinical, and immunological data for the patients were prospec-
tively collected as part of the Swiss HIV Cohort Study (5), and the patients ﬁlled
in a questionnaire on risks associated with diarrhea at the time of stool exami-
nation (16).
DNA puriﬁcation and PCR ampliﬁcation of 18S rDNA and acetyl-CoA syn-
thetase genes. DNA was puriﬁed as described previously (8). The ampliﬁcation
conditions used to amplify a 298-bp portion of the 18S ribosomal DNA (rDNA)
gene were as described previously (6). The primers and their sequences used to
amplify a 390-bp product from the acetyl coenzyme A (acetyl-CoA) synthetase
gene were as described previously (7). TAQ Extender (Stratagene, La Jolla,
Calif.) was included in all reaction mixtures to minimize PCR error.
PCR ampliﬁcation of the HSP-70 gene. A two-step nested PCR protocol was
used to amplify the heat shock gene (HSP-70 gene) from genomic DNA for
nucleotide sequencing. For the primary PCR, a PCR product of ;2,015 bp was
ampliﬁed with a forward primer (59-ATG TCT GAA GGT CCA GCT ATT
GGT ATT GA-39) and a reverse primer (59-TTA GTC GAC CTC TTC AAC
AGT TGG-39). The PCR mixture consisted of 50 ng of genomic DNA, each
deoxynucleoside triphosphate at a concentration of 200 mM, 13 PCR buffer
(Perkin-Elmer), 3.0 mM MgCl2,5 . 0Uo fTaq polymerase (GIBCO BRL), and 40
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1180ng of forward and reverse primers in a total reaction volume of 100 ml. Thirty-ﬁve
PCR cycles (94°C for 45 s, 55°C for 45 s, 72°C for 60 s) were carried out in a
Perkin-Elmer Gene Amp PCR 9700 thermocycler with an initial hot start (94°C
for 5 min) and a ﬁnal extension (72°C for 10 min). For the secondary PCR, a
fragment of ;1,950 bp was ampliﬁed by using 2.5 ml of primary PCR product and
nested forward (59-TA/CT TCA TG/CT GTT GGT GTA TGG AGA AA-39)
and nested reverse (59-CAA CAG TTG GAC CAT TAG ATC C-39) primers.
The PCR conditions for the secondary PCR were identical to those for the
primary PCR, except that the annealing temperature was 45°C.
Sequencing of PCR products. PCR products were puriﬁed by using Qiagen
spin columns (Qiagen, Hilden, Germany) and were sequenced by using an ABI
Prism Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City,
Calif.) according to the manufacturers’ instructions. PCR products were se-
quenced in both directions. Sequences were analyzed by using SeqEd, version
1.0.3 (Applied Biosystems).
RESULTS
Sequence analysis of the 18S rDNA gene. The 18S rDNA
gene locus of all 22 isolates was analyzed. DNA sequence
analysis at this locus identiﬁed four distinct genotypes, with the
cattle genotype being the most common genotype identiﬁed (8
of 22) (Table 1). Six isolates were of the human genotype.
Interestingly, a total of six isolates exhibited the C. felis geno-
type. Three of these isolates were from Switzerland and three
were from the United States. Two isolates (isolates CZ-H78
and Ke-H392), one from Switzerland and one from Kenya,
were identiﬁed as C. meleagridis.
Sequence analysis of the acetyl-CoA synthetase gene. The
acetyl-CoA synthetase gene locus of 14 isolates was examined.
A number of isolates, particularly those isolates which exhib-
ited the C. felis genotype, did not produce a product with the
acetyl-CoA synthetase gene-speciﬁc primers, presumably due
to genetic differences between C. felis and C. parvum (H/C) at
the primer binding sites. Sequence analysis of this locus iden-
tiﬁed three distinct genotypes: the cattle genotype, the human
genotype, and a distinct genotype exhibited by one isolate
(isolate Ke-H392) which typed as C. meleagridis at the 18S
rDNA gene locus. The genotyping results for the acetyl-CoA
synthetase gene locus were in agreement with those for the 18S
rDNA gene locus (Table 1).
Sequence analysis of the HSP-70 gene. The HSP-70 gene
locus of a smaller subset of isolates (n 5 11) was analyzed.
Four distinct genotypes were identiﬁed at this locus: human,
cattle, C. felis, and C. meleagridis (Table 1). Genotyping results
for this locus were in agreement with those for the 18S rDNA
and acetyl-CoA synthetase gene loci.
Clinical information. The majority of the clinical informa-
tion available in this study was obtained for HIV-infected pa-
tients from Zurich, Switzerland. These patients exhibited a va-
riety of other concurrent AIDS-deﬁning infections including
microsporidiosis, toxoplasmosis, and Kaposi’s sarcoma (Table
2). For all patients, CD4
1 lymphocyte counts were low and
ranged from 0 to 110 per ml. The main mode of HIV acquisi-
tion was via sexual contact. All patients were experiencing
chronic diarrhea that had lasted at least 4 weeks at the time of
evaluation. No concurrent infection was found in the three
C. felis-infected patients whose isolates were provided by the
Centers for Disease Control and Prevention. In particular,
patient US-HNO36/38 was positive twice for C. felis over a
5.5-month span and had diarrhea for the entire time.
DISCUSSION
Numerous studies of Cryptosporidium infections in HIV-
infected individuals have been conducted; however, few have
genotyped the Cryptosporidium isolates from these patients in
order to obtain more predictive epidemiological data as to the
sources of the infections. In this study, Cryptosporidium isolates
from HIV-infected individuals from Switzerland, Kenya, and
the United States were analyzed at three genetic loci: the 18S
rDNA, HSP-70, and acetyl-CoA synthetase gene loci. The re-
sults revealed that the majority of the patients (64%) were
infected with the human and cattle C. parvum genotypes. How-
ever, a number of patients were infected with C. felis (27%) or
C. meleagridis (9%). This is the ﬁrst report of C. meleagridis
infection in a human host.
Few genotyping studies have been conducted with isolates of
Cryptosporidium from HIV-infected patients (2, 13, 15, 17). In
TABLE 1. Isolates and genotypes of Cryptosporidium used in this study
Isolate code Geographical
location Source
a
Genotype by analysis of:
18S rDNA gene Acetyl-CoA synthetase gene HSP-70 gene
CH-H66 Switzerland USZ Cattle Cattle
CH-H67 Switzerland USZ C. felis
CH-H68 Switzerland USZ Cattle Cattle Cattle
CH-H69 Switzerland USZ Cattle Cattle
CH-H71 Switzerland USZ C. felis
CH-H73 Switzerland USZ Cattle Cattle
CH-H74 Switzerland USZ Cattle Cattle Cattle
CH-H75 Switzerland USZ Cattle Cattle
CH-H77 Switzerland USZ C. felis
CH-H78 Switzerland USZ C. meleagridis
CH-H79 Switzerland USZ Human Human Human
CH-H80 Switzerland USZ Cattle
CH-H81 Switzerland USZ Human Human
Ke-H271 Kenya KEMRI Cattle Cattle Cattle
Ke-H289 Kenya KEMRI Human Human
Ke-H392 Kenya KEMRI C. meleagridis C. meleagridis C. meleagridis
Ke-H375 Kenya KEMRI Human Human Human
Ke-H155 Kenya KEMRI Human Human Human
Ke-H189 Kenya KEMRI Human Human Human
US-HNO2 United States CDC C. felis C. felis
US-HNO21 United States CDC C. felis C. felis
US-HNO36/38 United States CDC C. felis C. felis
a USZ, University Hospital, Zurich, Switzerland; KEMRI, Kenya Medical Research Institute; CDC, Centers for Disease Control and Prevention, Atlanta, Ga.
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C. parvum isolates from HIV-infected patients. Isolates from
ﬁve of the patients tested exhibited the human genotype and
isolates from two patients exhibited the cattle genotype (17).
No genotypic information was obtained for isolates from two
subjects; the oocysts from one failed to be ampliﬁed by any of
the PCR primers used, and the second isolate was ampliﬁed
with only the 18S rDNA gene-speciﬁc primers (17). A possible
reason for this is that the oocysts detected in these two patients
were not of the human or cattle genotype. Experience in our
laboratories has shown that primers that are speciﬁc for Cryp-
tosporidium but that have been designed on the basis of the
human and cattle genotypes frequently do not amplify more
genetically diverse genotypes such as the pig or dog genotypes
of C. parvum or other species of Cryptosporidium.
A more recent study genotyped the 18S rDNA gene locus of
10 Cryptosporidium isolates from HIV-infected individuals
(13). In that study, one isolate exhibited the cattle genotype,
ﬁve isolates exhibited the human genotype, three isolates ex-
hibited the C. felis genotype, and one isolate exhibited the
newly identiﬁed dog genotype (13). For some patients, multi-
ple specimens collected over 12 months were available, and for
these patients the same Cryptosporidium genotype persisted
throughout the course of the patient’s infection (13).
Epidemiological investigations on the mode of transmission
or the possible sources of human cryptosporidial infections are
difﬁcult because there are two possible pathogenetic mecha-
nisms of cryptosporidial disease: ﬁrst, HIV-infected patients
with clinically manifest cryptosporidiosis may have very re-
cently acquired cryptosporidial infection (a new exogenous
infection); and second, infection may have occurred earlier,
possibly prior to the state of immunodeﬁciency, and the infec-
tion was activated due to the progression of the immunodeﬁ-
ciency (an endogenous activation of latent infection).
In the present study, three of the six patients infected with
C. felis had reported having a cat as a pet. It is therefore likely
that they acquired their infections from their pets. For the
remaining three patients infected with C. felis, no pets were re-
corded. However, it is possible that these patients had been
exposed to cats at some time prior to the onset of clinically
apparent cryptosporidiosis. One of the patients infected with
C. meleagridis reported having only a cat as a pet, but clinical
information was not obtained for the second patient who was
infected with C. meleagridis. C. meleagridis normally infects tur-
keys (4). However, this species has recently been conﬁrmed in
an Indian ring-necked parrot, which is a common aviary bird
with a worldwide distribution (10). C. meleagridis may there-
fore have a much wider host range than was previously
thought, and it is possible that these patients acquired their
cryptosporidial infections via contact with aviary birds.
Recent studies have reported that among HIV-infected in-
dividuals, those with CD4
1 lymphocyte counts of ,100 3 10
6/
liter are at increased risk of contracting clinical cryptosporidi-
osis (12, 14, 16). All the patients in the present study were
suffering from chronic diarrhea, and the majority of the pa-
tients in this study had other concurrent AIDS-deﬁning infec-
tions, such as toxoplasmosis or microsporidiosis (Table 2). The
majority of patients had CD4
1 lymphocyte counts which were
,100 3 10
6/liter, and in most patients the counts were less
than 50 3 10
6/liter. In two patients (CZ-H77 and CZ-H78),
the CD4
1 lymphocyte counts were 0 (Table 2). However, the
small number of samples available does not allow any hypoth-
eses regarding the different clinical courses to be made.
The majority of Cryptosporidium isolates from HIV-infected
individuals from Switzerland exhibited the cattle genotype
(54%). In previous studies with immunocompetent human-
derived Cryptosporidium isolates from Perth, Western Austra-
lia, the human genotype was the most common genotype iden-
tiﬁed (83%; n 5 36) (8). Whether there are differences in the
predominance and distribution of the human and cattle geno-
types between different geographic areas and whether the cat-
tle genotype is more predominant among HIV-infected per-
sons are issues which warrant future investigation.
Six of the isolates examined in this study were from Kenya;
four of these were of the human genotype, and the remaining
two (isolates Ke-H271 and Ke-H392) were of the cattle geno-
type and C. meleagridis, respectively. Little is known about the
prevalence of Cryptosporidium in African countries, and this
is the ﬁrst time that Cryptosporidium isolates from Kenyan
HIV-infected patients have been analyzed genetically. Recent
research, however, indicates that the prevalence of Cryptospo-
ridium in African HIV-infected patients may be high. A pro-
spective cross-sectional study of 75 consecutive HIV-sero-
positive adult patients admitted to a government hospital in
Nairobi, Kenya, revealed that Cryptosporidium was the most
common pathogen (17%). Thirty-one (41%) patients died, and
detection of Cryptosporidium oocysts was the single most sig-
niﬁcant predictor of death (x
2 5 5.2; P ,0.05) (11). These
results are in agreement with those of an earlier study per-
formed in Nairobi, Kenya (1). The study reported that Shigella
TABLE 2. Clinical and epidemiological data for HIV-infected patients with Cryptosporidium infections from Zurich and the United States
Isolate code Mode of HIV
acquisition
Other concurrent AIDS-deﬁning
infections
CD4 lymphocyte
count (no./ml)
Genotype,
species Pets
CZ-H66 Homosexual activity Candida esophagitis 20 Cattle, C. parvum Cat, dog
CZ-H67 Homosexual activity None 60 C. felis Cat
CZ-H68 Homosexual activity Toxoplasmosis, Kaposi’s sarcoma 20 Cattle, C. parvum None
CZ-H69 Intravenous drug use Candida esophagitis 20 Cattle, C. parvum Cat
CZ-H71 Homosexual activity Esophagitis, microsporidiosis 30 C. felis None
CZ-H73 Homosexual activity Cytomegalovirus retinitis 10 Cattle, C. parvum None
CZ-H74 Homosexual activity Microsporidiosis 110 Cattle, C. parvum Dog
CZ-H75 Homosexual activity Kaposi’s sarcoma, cytomegalovirus retinitis 20 Cattle, C. parvum None
CZ-H77 Intravenous drug use Disseminated nontuberculous mybobacteriosis 0 C. felis Cat
CZ-H78 Homosexual activity Disseminated nontuberculous mycobacteriosis,
Kaposi’s sarcoma
0 C. meleagridis Cat
CZ-H79 Homosexual activity None 10 Human, C. parvum Cat
CZ-H80 Homosexual activity Isosporiasis, Candida esophagitis 40 Cattle, C. parvum Snake
CZ-H81 Homosexual activity Tuberculosis, Kaposi’s sarcoma, cytomegalovirus retinitis 54 Human, C. parvum None
US-HNO2 Intravenous drug use None (history of syphilis) 48 C. felis None
US-HNO21 Homosexual activity None (history of Kaposi’s sarcoma, Candida esophagitis) 38 C. felis Cat, bird, dog
US-HNO36/38 Congenital transmission 3 C. felis
1182 MORGAN ET AL. J. CLIN.M ICROBIOL.ﬂexneri, Salmonella enterica serovar Typhimurium, and C. par-
vum were the most common fecal pathogens among HIV-
infected and non-HIV-infected individuals studied (1).
In conclusion, the results of the present study and those of
other studies indicate that immunocompromised individuals
are susceptible to a wide range of Cryptosporidium species and
genotypes and that host factors must play a role in controlling
susceptibility to these divergent parasites. Future studies with
larger numbers of AIDS patients for whom more extensive
clinical information is available are required in order to un-
derstand the full public health signiﬁcance of Cryptosporidium
species and genotypes in immunocompromised hosts.
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